Settle Terms Before Brexit Divorce Is Final, Former EMA Chief Says
Executive Summary
If the European Medicines Agency has to desert London as a result of the UK’s decision to leave the EU, it will have to take care in managing issues such as the loss of expert input from the UK regulator, the MHRA, says former EMA head Thomas Lönngren.
You may also be interested in...
Brexit: EMA To Bolster Regulatory Reserves Ahead Of Relocation
European Medicines Agency head Guido Rasi explains the measures being taken to soften the blow of its departure from the UK, while a former health commissioner says that a decision needs to be taken as soon as possible on where the agency will be sited in order to ensure a smooth transition before Brexit.
Japan Wants EMA To Stay In UK Post-Brexit
The assumption to date has been that the European Medicines Agency will have to relocate from London to another EU member state when the UK leaves the EU. Japan says it should stay. Also, Emer Cooke, the EMA’s head of international affairs, is leaving the agency.
UK Pharma's 'Brexit Playbook' Might Envision New Regulator Roles
Britain's life sciences sector is compiling detailed game plan for September talks with the new Conservative government to promote its interests once the UK leaves the EU. All options are being considered – including possible establishment of a best-in-class regulatory agency in Britain.